Skip to content
10-Q

Quarterly Report

MERRIMACK PHARMACEUTICALS INC

0000950170-24-060478

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 13, 2024 14.79M sh
Shares Diluted Q1 2024 · Mar 31, 2024 14.45M sh
Shares Diluted Q1 2024 · Mar 31, 2023 14.25M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$1.31M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$356K
Short Term Investments Q1 2024 · Mar 31, 2024 $9.95M
Short Term Investments Q1 2024 · Dec 31, 2023 $12.89M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $234.16M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $5.99M
Stockholders Equity Q1 2024 · Mar 31, 2024 $221.65M
Stockholders Equity Q1 2024 · Dec 31, 2023 $18.75M
Stockholders Equity Q1 2024 · Mar 31, 2023 $19.17M
Stockholders Equity Q1 2024 · Dec 31, 2022 $19.25M
Current Liabilities Q1 2024 · Mar 31, 2024 $22.67M
Current Liabilities Q1 2024 · Dec 31, 2023 $441K
Total Liabilities Q1 2024 · Mar 31, 2024 $22.67M
Total Liabilities Q1 2024 · Dec 31, 2023 $441K
Current Assets Q1 2024 · Mar 31, 2024 $244.32M
Current Assets Q1 2024 · Dec 31, 2023 $19.18M
Total Assets Q1 2024 · Mar 31, 2024 $244.32M
Total Assets Q1 2024 · Dec 31, 2023 $19.19M
Eps Diluted Q1 2024 · Mar 31, 2024 $13.93
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.02
Eps Basic Q1 2024 · Mar 31, 2024 $13.93
Eps Basic Q1 2024 · Mar 31, 2023 −$0.02
Operating Income Q1 2024 · Mar 31, 2024 −$669K
Operating Income Q1 2024 · Mar 31, 2023 −$447K